Bausch + Lomb refinances term loans, extends maturities

Bausch + Lomb Corporation ( (BLCO) ) has shared an update.

On January 2, 2026, Bausch + Lomb Corporation closed a refinancing of its existing credit facilities by entering into a fourth amendment to its credit agreement, establishing a new $2.80 billion tranche of term B loans maturing on January 15, 2031. The proceeds were used to refinance all of the company’s outstanding term B loans due 2031 and 2028, effectively extending the maturity of the 2028 loans to 2031 while lowering borrowing costs by reducing the applicable margins by 0.50 percentage points and 0.25 percentage points, respectively; the new loans amortize at 1.00% per year starting June 30, 2026, signaling an effort to optimize Bausch + Lomb’s capital structure and potentially improve its interest expense profile over time.

The most recent analyst rating on (BLCO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Spark’s Take on BLCO Stock

According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.

Bausch + Lomb’s stock score is driven by strong revenue growth and positive technical indicators. However, profitability challenges and a negative P/E ratio weigh on the valuation. The earnings call highlights strategic resilience, but operational efficiency improvements are needed.

To see Spark’s full report on BLCO stock, click here.

More about Bausch + Lomb Corporation

Bausch + Lomb Corporation is a leading global eye health company that develops and markets a broad portfolio of products, including contact lenses, prescription ophthalmic medicines, over-the-counter eye care products and surgical devices, with a mission focused on improving vision and eye health for patients worldwide.

Average Trading Volume: 430,264

Technical Sentiment Signal: Buy

Current Market Cap: $6.05B

Find detailed analytics on BLCO stock on TipRanks’ Stock Analysis page.